
Health Catalyst, Inc.
HCATNASDAQHealthcareMedical - Healthcare Information Services
Latest quote
$1.54
−$0.10 · -6.13%
HCAT company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
52
Fair Value
Momentum
48
Neutral
Sentiment
43
Mixed
Risk resilience
29
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteHealth Catalyst, Inc. equips healthcare providers with crucial data and analytical technologies, alongside specialized services. Their extensive product line features a robust, enterprise-level data and analytics platform designed specifically for the healthcare sector. They additionally offer advanced artificial intelligence (AI) and data science solutions that integrate AI seamlessly into existing business intelligence tools, thereby enhancing analytical precision. The company's services also cover population health management, which identifies areas for improvement throughout the patient care journey, offering actionable recommendations and automated processes. For financial effectiveness, they provide critical insights into cost analysis, workforce efficiency, and revenue maximization. Moreover, Health Catalyst contributes to improving quality and safety by leveraging clinical and patient safety data, sophisticated analytics, and expert consulting. They also facilitate a national data ecosystem, promoting collaborative thought leadership and shared knowledge to generate groundbreaking insights that redefine healthcare delivery. Established in 2008 and based in South Jordan, Utah, the company was formerly known as HQC Holdings, Inc. before officially becoming Health Catalyst, Inc. in March 2017.
- Industry
- Medical - Healthcare Information Services
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Benjamin Albert
- Listed since
- Jul 25, 2019
- Employees
- 1,200
Market position
- Volume
- 1.06M
- 0.8× average
- Average volume
- 1.34M
- Average daily volume
- Market cap
- 113.06M USD
- Beta
- 1.56
- Market reference 1
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 287.48M USD
- P/E (TTM)
- -0.42×
- P/B (TTM)
- 1.12×
- P/S (TTM)
- 0.39×
- EV / EBITDA
- -2.61×
- Earnings yield
- -106.54%
- Free cash flow yield
- -0.14%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 46.44%
- Operating margin
- -19.67%
- Net margin
- -90.61%
- Return on equity
- -72.41%
- Return on assets
- -35.41%
- Return on invested capital
- -8.63%
Financial health
- Debt / equity
- 1.69×
- Current ratio
- 1.89×
- Altman Z-score
- -6.6
- Piotroski F-score
- 5 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 311.14M USD | 306.58M USD | 295.94M USD | 276.24M USD | 241.93M USD |
| Cost of goods sold | 207M USD | 165.81M USD | 164.11M USD | 143.05M USD | 124.35M USD |
| Gross profit | 104.13M USD | 140.78M USD | 131.83M USD | 133.19M USD | 117.57M USD |
| Research and development | 49.77M USD | 57.95M USD | 72.63M USD | 75.68M USD | 62.73M USD |
| Selling, general, and administrative | 102.04M USD | 111.2M USD | 143.88M USD | 149.22M USD | 160.96M USD |
| Operating expenses | 140.24M USD | 210.59M USD | 258.73M USD | 273.19M USD | 261.22M USD |
| Interest income | 7.54M USD | 17.98M USD | 16.39M USD | 5.69M USD | 831K USD |
| Interest expense | 16.4M USD | 17.09M USD | 7.29M USD | 7.24M USD | 17.31M USD |
| Depreciation and amortization | 50.5M USD | 41.43M USD | 42.22M USD | 51.53M USD | 41.11M USD |
| Operating income | −36.1M USD | −69.81M USD | −126.9M USD | −140.01M USD | −143.65M USD |
| Net income | −177.97M USD | −69.5M USD | −118.15M USD | −137.4M USD | −153.21M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 64%
- 7 beats, 3 misses, 1 met estimate
- Average EPS surprise
- +264.70%
- 11 comparable reports
- Latest EPS result
- 0.04
- Estimate 0.03 · Beat by 33.87%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$2.08
35.95% upsidePrice history unavailable
High $3.00Average $2.08Low $1.75Rating distribution
22 ratingsRecent analyst actions
HCAT news
HCAT peers
Continue in GoAI
Research HCATresearch.disclaimer











